REPLIGEN Business Summary

Repligen Corporation (RGEN) is a specialized life sciences company that generates revenue through the development and commercialization of high-margin bioprocessing technologies and consumables used in biologic drug manufacturing. The company’s business is organized into four primary segments: Filtration (58% of revenue), Chromatography (19%), Proteins (12%), and Process Analytics (9%). Its operational model focuses on providing essential single-use systems and components that enhance yield and efficiency for biopharmaceutical firms and contract development and manufacturing organizations (CDMOs). Repligen competes directly with large-scale diversified peers such as Danaher Corporation (via Cytiva and Pall), Sartorius Stedim Biotech, Merck KGaA (MilliporeSigma), and Thermo Fisher Scientific. Within this landscape, Repligen maintains a dominant niche as a pure-play innovation leader in downstream processing and digitized process analytical technology (PAT). Founded in 1981 by MIT professors Paul Schimmel and Alexander Rich, Repligen is currently led by President and CEO Olivier Loeillot, who succeeded long-time leader Tony Hunt in September 2024 following a career at Lonza and Cytiva. The executive team includes Jason K. Garland as Chief Financial Officer, James R. Bylund as Chief Operating Officer, and Ralf Kuriyel as Senior Vice President of Research and Development. As of February 2026, Tony Hunt serves as Executive Chairman of the Board, with Dr. Martin D. Madaus—former CEO of Millipore—slated to transition to the Chair role in March 2026. The company maintains a high degree of institutional backing, with major stakeholders including T. Rowe Price Group, BlackRock, and The Vanguard Group, alongside notable board oversight from Lead Independent Director Karen A. Dawes.